• +1-646-491-9876
    • +91-20-67278686

    Search

    Diabetic Macular Edema - Pipeline Review, H1 2017

    Diabetic Macular Edema - Pipeline Review, H1 2017

    • Report Code ID: RW0001689453
    • Category Healthcare
    • No. of Pages 188
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema - Pipeline Review, H1 2017, provides an overview of the Diabetic Macular Edema (Metabolic Disorders) pipeline landscape.

    Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Diabetic Macular Edema - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Diabetic Macular Edema (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 20, 5, 1, 18 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

    Diabetic Macular Edema (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders).
    - The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 5
    List of Figures 6
    Introduction 7
    Publisher Report Coverage 7
    Diabetic Macular Edema - Overview 8
    Diabetic Macular Edema - Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 14
    Products under Development by Companies 15
    Products under Development by Universities/Institutes 18
    Diabetic Macular Edema - Therapeutics Assessment 19
    Assessment by Target 19
    Assessment by Mechanism of Action 22
    Assessment by Route of Administration 26
    Assessment by Molecule Type 28
    Diabetic Macular Edema - Companies Involved in Therapeutics Development 30
    Aciont Inc 30
    ActiveSite Pharmaceuticals Inc 30
    Acucela Inc 31
    Aerpio Therapeutics Inc 31
    Allergan Plc 32
    Ampio Pharmaceuticals Inc 32
    Araim Pharmaceuticals Inc 33
    Boehringer Ingelheim GmbH 33
    Cell Medica Ltd 34
    Chengdu Kanghong Pharmaceuticals Group Co Ltd 34
    Chong Kun Dang Pharmaceutical Corp 35
    Clearside BioMedical Inc 35
    Coherus BioSciences Inc 36
    EyeGate Pharmaceuticals Inc 36
    F. Hoffmann-La Roche Ltd 37
    Formycon AG 37
    Genmab A/S 38
    GlaxoSmithKline Plc 38
    Icon Bioscience Inc 39
    Kala Pharmaceuticals Inc 39
    Kalvista Pharmaceuticals Ltd 40
    Kowa Company Ltd 40
    Lupin Ltd 41
    Mabion SA 41
    Oculis ehf 42
    Ohr Pharmaceutical Inc 42
    Oxular Ltd 43
    Pfizer Inc 43
    pSivida Corp 44
    Regeneron Pharmaceuticals Inc 44
    Santen Pharmaceutical Co Ltd 45
    SciFluor Life Sciences LLC 45
    Senju Pharmaceutical Co Ltd 46
    Stealth BioTherapeutics Inc 46
    ThromboGenics NV 47
    Verseon Corp 47
    Xbrane Biopharma AB 48
    Diabetic Macular Edema - Drug Profiles 49
    (aflibercept + nesvacumab) - Drug Profile 49
    abicipar pegol - Drug Profile 51
    ACU-6151 - Drug Profile 55
    ACX-107 - Drug Profile 56
    aflibercept biosimilar - Drug Profile 57
    aflibercept biosimilar - Drug Profile 58
    AKB-9778 - Drug Profile 59
    ALG-1001 - Drug Profile 63
    Antibodies to Inhibit Hemopexin for Diabetic Macular Edema - Drug Profile 67
    ARP-1536 - Drug Profile 68
    ASPPDC-010 - Drug Profile 69
    BI-1026706 - Drug Profile 70
    Biologics to Inhibit Semaphorin 3A and VEGF for Diabetic Complications - Drug Profile 72
    brolucizumab - Drug Profile 73
    bromfenac sodium - Drug Profile 75
    cibinetide - Drug Profile 76
    conbercept - Drug Profile 79
    danazol - Drug Profile 81
    darapladib - Drug Profile 85
    dexamethasone acetate - Drug Profile 88
    dexamethasone acetate - Drug Profile 93
    dexamethasone dipropionate XR - Drug Profile 94
    dexamethasone palmitate - Drug Profile 95
    difluprednate - Drug Profile 96
    Drug for Diabetic Macular Edema - Drug Profile 97
    EBI-031 - Drug Profile 98
    elamipretide - Drug Profile 99
    fluocinolone acetonide SR - Drug Profile 107
    HO-10 - Drug Profile 116
    JDE-006 - Drug Profile 117
    KPI-285 - Drug Profile 118
    KVD-001 - Drug Profile 119
    LKA-651 - Drug Profile 121
    loteprednol etabonate - Drug Profile 122
    NM-108 - Drug Profile 125
    PF-655 - Drug Profile 126
    ranibizumab biosimilar - Drug Profile 129
    ranibizumab biosimilar - Drug Profile 130
    ranibizumab biosimilar - Drug Profile 131
    ranibizumab biosimilar - Drug Profile 133
    ranibizumab biosimilar - Drug Profile 134
    ranibizumab biosimilar - Drug Profile 135
    RG-7716 - Drug Profile 136
    ripasudil - Drug Profile 138
    SF-0166 - Drug Profile 140
    Small Molecule for Diabetic Macular Edema - Drug Profile 142
    Small Molecule to Inhibit LP-PLA2 for Diabetic Macular Edema - Drug Profile 143
    Small Molecules to Inhibit Plasma Kallikrein for Diabetic Macular Edema - Drug Profile 144
    squalamine lactate - Drug Profile 145
    teprotumumab - Drug Profile 153
    TG-931 - Drug Profile 155
    THR-149 - Drug Profile 156
    THR-317 - Drug Profile 157
    triamcinolone acetonide - Drug Profile 160
    triamcinolone acetonide - Drug Profile 161
    VA-999272 - Drug Profile 167
    Diabetic Macular Edema - Dormant Projects 168
    Diabetic Macular Edema - Discontinued Products 170
    Diabetic Macular Edema - Product Development Milestones 171
    Featured News & Press Releases 171
    Appendix 183
    Methodology 183
    Coverage 183
    Secondary Research 183
    Primary Research 183
    Expert Panel Validation 183
    Contact Us 183
    Disclaimer 184

    List of Tables

    Number of Products under Development for Diabetic Macular Edema, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Diabetic Macular Edema - Pipeline by Aciont Inc, H1 2017
    Diabetic Macular Edema - Pipeline by ActiveSite Pharmaceuticals Inc, H1 2017
    Diabetic Macular Edema - Pipeline by Acucela Inc, H1 2017
    Diabetic Macular Edema - Pipeline by Aerpio Therapeutics Inc, H1 2017
    Diabetic Macular Edema - Pipeline by Allergan Plc, H1 2017
    Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals Inc, H1 2017
    Diabetic Macular Edema - Pipeline by Araim Pharmaceuticals Inc, H1 2017
    Diabetic Macular Edema - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Diabetic Macular Edema - Pipeline by Cell Medica Ltd, H1 2017
    Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2017
    Diabetic Macular Edema - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2017
    Diabetic Macular Edema - Pipeline by Clearside BioMedical Inc, H1 2017
    Diabetic Macular Edema - Pipeline by Coherus BioSciences Inc, H1 2017
    Diabetic Macular Edema - Pipeline by EyeGate Pharmaceuticals Inc, H1 2017
    Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Diabetic Macular Edema - Pipeline by Formycon AG, H1 2017
    Diabetic Macular Edema - Pipeline by Genmab A/S, H1 2017
    Diabetic Macular Edema - Pipeline by GlaxoSmithKline Plc, H1 2017
    Diabetic Macular Edema - Pipeline by Icon Bioscience Inc, H1 2017
    Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals Inc, H1 2017
    Diabetic Macular Edema - Pipeline by Kalvista Pharmaceuticals Ltd, H1 2017
    Diabetic Macular Edema - Pipeline by Kowa Company Ltd, H1 2017
    Diabetic Macular Edema - Pipeline by Lupin Ltd, H1 2017
    Diabetic Macular Edema - Pipeline by Mabion SA, H1 2017
    Diabetic Macular Edema - Pipeline by Oculis ehf, H1 2017
    Diabetic Macular Edema - Pipeline by Ohr Pharmaceutical Inc, H1 2017
    Diabetic Macular Edema - Pipeline by Oxular Ltd, H1 2017
    Diabetic Macular Edema - Pipeline by Pfizer Inc, H1 2017
    Diabetic Macular Edema - Pipeline by pSivida Corp, H1 2017
    Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals Inc, H1 2017
    Diabetic Macular Edema - Pipeline by Santen Pharmaceutical Co Ltd, H1 2017
    Diabetic Macular Edema - Pipeline by SciFluor Life Sciences LLC, H1 2017
    Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co Ltd, H1 2017
    Diabetic Macular Edema - Pipeline by Stealth BioTherapeutics Inc, H1 2017
    Diabetic Macular Edema - Pipeline by ThromboGenics NV, H1 2017
    Diabetic Macular Edema - Pipeline by Verseon Corp, H1 2017
    Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, H1 2017
    Diabetic Macular Edema - Dormant Projects, H1 2017
    Diabetic Macular Edema - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Diabetic Macular Edema - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Diabetic Macular Edema, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Aciont Inc
    ActiveSite Pharmaceuticals Inc
    Acucela Inc
    Aerpio Therapeutics Inc
    Allergan Plc
    Ampio Pharmaceuticals Inc
    Araim Pharmaceuticals Inc
    Boehringer Ingelheim GmbH
    Cell Medica Ltd
    Chengdu Kanghong Pharmaceuticals Group Co Ltd
    Chong Kun Dang Pharmaceutical Corp
    Clearside BioMedical Inc
    Coherus BioSciences Inc
    EyeGate Pharmaceuticals Inc
    F. Hoffmann-La Roche Ltd
    Formycon AG
    Genmab A/S
    GlaxoSmithKline Plc
    Icon Bioscience Inc
    Kala Pharmaceuticals Inc
    Kalvista Pharmaceuticals Ltd
    Kowa Company Ltd
    Lupin Ltd
    Mabion SA
    Oculis ehf
    Ohr Pharmaceutical Inc
    Oxular Ltd
    Pfizer Inc
    pSivida Corp
    Regeneron Pharmaceuticals Inc
    Santen Pharmaceutical Co Ltd
    SciFluor Life Sciences LLC
    Senju Pharmaceutical Co Ltd
    Stealth BioTherapeutics Inc
    ThromboGenics NV
    Verseon Corp
    Xbrane Biopharma AB

    Request for Sample

    Report Url http://www.reportsweb.com//diabetic-macular-edema-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//diabetic-macular-edema-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//diabetic-macular-edema-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments